Read all about the latest news and headlines of Galderma USA activities. In just
a click away.
THE
AMERICAN ACADEMY OF DERMATOLOGY AND GALDERMA ANNOUNCE NEW, INNOVATIVE RESEARCH FELLOWSHIP
- The new fellowship offers a dermatologist the opportunity to work in drug development
and translational medical research at Galderma’s R&D facility located in Sophia
Antipolis, France.
EPIDUO®
GEL BECOMES FIRST TOPICAL PRESCRIPTION ACNE TREATMENT AVAILABLE FOR CHILDREN AS
YOUNG AS 9 YEARS-OLD
- FDA-Approval Provides Pediatricians and Dermatologists with Safe and Effective
Treatment for Younger Children Suffering from Acne
EPIDUO®
TAP PROGRAM MAY INCREASE PATIENT ADHERENCE TO ACNE TREATMENT
- Multi-Media Program Provides Epiduo® Gel Patients with Tools to
Track Treatment.
NUVO RESEARCH ANNOUNCES U.S. LAUNCH OF PLIAGLIS® BY GALDERMA
- Pliaglis® is indicated for use on intact skin in adults to provide local analgesia
for superficial aesthetic procedures.
Galderma’s
Tri-Luma Cream®, Only FDA-Approved Treatment for Melasma, Now Available
in Pharmacies
- Clinically Proven Treatment Can Help More than 7 Million Suffering from Melasma
in the U.S.
Nuvo and Galderma Announce FDA Approval of Pliaglis®
- Pliaglis Offers a Pre-Treatment Topical Solution and Contributes to Improving
the Patient Experience of Aesthetic Procedures
The Cetaphil® Brand Teams with Camp Wonder
- To Give Children With Serious Skin Diseases the Chance to Be Kids
Fort Worth-Based Galderma Laboratories Pledges Additional $450, 000 for Dermatology
Program
- A Residency Program At Baylor Dallas To Educate the Next Generation of Dermatologists
in North Texas
Actress Cynthia Nixon Reveals
How Rosacea Has Impacted Her Life
- New Public Service Announcement Encourages Awareness and Diagnosis of Common Skin
Condition During Rosacea Awareness Month in April
Galderma
Announces Completion of Phase 3 Trials of Investigational Drug Targeting Facial
Erythema of Rosacea
- Phase 3 Trials Confirm Findings of Phase 2 Studies
Cetaphil®
Brand Launches Cetaphil® DermaControl™, A New Line of Products for Acne-prone Skin
- Introducing Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF30, Specially
Designed for Patients with Acne-Prone Skin
Galderma
Receives FDA Approval for New Convenient Pump Dispenser of Differin® Gel, 0.3% For
Treatment of Acne Vulgaris
- Acne Sufferers Prefer Pump Over Tube Delivery, Patient Preference Survey Shows
Galderma
Announces Availability of New MetroGel® 1% Pump Dispenser for the Treatment of Papulopustular
Rosacea
- Pump Delivery Provides Consistent Dosing, Minimizes Waste and May Help Increase
Patient Compliance
#1 Branded
Topical Acne Product, Epiduo® Gel, Receives FDA for A New Convenient Pump Dispenser
- Study Shows that Acne Sufferers Prefer Pump Delivery for Treatment Administration